Laevoroc Oncology pushes for relapsed leukemia cure

leukaemia leukemia

Laevoroc Oncology, a privately-owned, Swiss oncology development company, has announced the publication of key preclinical data carried out at the University of California, Los Angeles (UCLA), which provides mechanistic insights into the immunoregulatory functions of purine nucleoside phosphorylase (PNP) with Laevoroc’s PNP inhibitor, LR 09.

The research shows that PNP is a novel metabolic immune checkpoint and LR 09 (Ulodesine), originally developed, and approved, for the treatment of gout, is a metabolic immune checkpoint inhibitor that activates the immune system through release of cytokines, expansion of germinal center B-cells and follicular helper T-cells.  

Relapse post-transplantation is the most frequent cause of treatment failure, in children and adults with leukemia. LR 09 has demonstrated an excellent safety profile in the clinic and is formulated as an oral once-a-day treatment. Relapsed leukemia places a heavy economic burden on health systems. In the U.S. healthcare setting, the mean total episode cost (from relapse date to death or end of study period), in a sample of around 700 patients, has been estimated, in 2019, at around $439,000 per patient.

Laevoroc Oncology’s approach combat host leukemia

Laevoroc Oncology’s co-founder and CEO, Thomas Mehrling, said: “We are delighted to have achieved this discovery with UCLA, which supports our vision for LR 09 to enable the treatment of relapsed leukemia — a devastating diagnosis for the patient and their families and an important cost burden for healthcare systems. Using our approach, we can help the grafted immune system recognize and combat the host leukemia, resulting in long-term response or cure.”

Laevoroc Oncology’s CSO, Shanta Bantia, said: “We believe our innovation is a game-changing new therapy with the potential to become standard of care. Our vision with LR 09 is to enable the cure of relapsed leukemia.” 

Laevoroc Oncology continues to focus on fundraising to bring LR 09 to the clinic, and to patients, as swiftly as possible. Laevoroc acquired the commercial rights to LR 09 for new indications in 2021.

The company has raised more than $1.1 million in seed finance, and is actively raising series A financing for its subsidiaries.

Partnering 2030: The Biotech Perspective 2023

Download Inpart’s latest report revealing the priorities of out-licensers worldwide.
Explore other topics: CancerResearchSwitzerlandT-cells

Newsletter Signup - Under Article / In Page

"*" indicates required fields

Subscribe to our newsletter to get the latest biotech news!

This field is for validation purposes and should be left unchanged.